Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies.
External genital and anal warts (acuminate condyloma) were the first medical indication the topical immune response modifier imiquimod was approved for in 1997. Since then, many placebo controlled randomized clinical trials have demonstrated the efficacy and safety of this synthetic imidazoquinoline derivate for the treatment of different human papillomavirus infections and tumours. Treatment modalities for genital warts (5% cream, three times weekly, minimum duration 4 weeks, control of side-effects) have been optimized and assured by further clinical trials and meta-analyses. For a few years clinical studies focussed on the long-term efficacy of the immunomodulatory therapy (sustained clearance from warts) and most recent studies compared the efficacy of ablative, destructive and imiquimod monotherapy as well as combination therapies.
Schöfer
H
H
Department of Dermatology and Venerology, University Hospital, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt/M, Germany. Schoefer@em.uni-frankfurt.de
D000634:Aminoquinolines / Q000627:therapeutic use*; D001004:Anus Diseases / Q000188:drug therapy / Q000601:surgery; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy / Q000601:surgery; D005832:Genital Diseases, Male / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
D000634:Aminoquinolines; D007369:Interferon Inducers; D000077271:Imiquimod